SCHEMBL1374190

SCHEMBL1374190

C(=NCCC1CNCCO1)=NC1CCCCC1.CCPCC

nearest known ligand 0.39

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.39
EPHX1 P07099 1/20 0.32
HIF1A Q16665 1/20 0.32
CYP2C9 P11712 1/20 0.31
ADRB2 P07550 1/20 0.30
HTR1A P08908 1/20 0.30
SLC6A2 P23975 1/20 0.30
HTR2A P28223 1/20 0.30
SLC6A4 P31645 1/20 0.30
ADRA1A P35348 1/20 0.30
HTR2B P41595 1/20 0.30
SLC6A3 Q01959 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6068742 0.92 CYP1A2 (0.45) CYP1A2EPHX1HIF1ACYP2C9SLC6A2
Hydrochloric Acid SCHEMBL27783235 0.90 CYP1A2 (0.44) CYP1A2EPHX1HIF1ACYP2C9HTR2A
Dicyclohexylcarbodiimide SCHEMBL11813048 0.89 CYP1A2 (0.37) CYP1A2EPHX1HIF1AADRB2HTR1A
Phosphoric Acid SCHEMBL28832745 0.85 CYP1A2 (0.40) CYP1A2EPHX1HIF1ACYP2C9
Diethyl Hydrogen Phosphate SCHEMBL27840807 0.83 CYP1A2 (0.35) CYP1A2CYP2C9ADRB2HTR1ASLC6A2
SCHEMBL6509489 0.79 CYP1A2 (0.40) CYP1A2EPHX1HIF1AADRB2HTR1A
SCHEMBL27902050 0.75 CYP2C9 (0.47) CYP1A2CYP2C9ADRB2HTR1ASLC6A2
SCHEMBL8170852 0.75 CYP2C9 (0.41) CYP1A2CYP2C9SLC6A2SLC6A4
SCHEMBL6817229 0.75 CYP2C9 (0.41) CYP1A2CYP2C9
SCHEMBL7147430 0.69 CYP1A2 (0.52) CYP1A2EPHX1HIF1ACYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8791102-B2 Acetanilide sphingosine-1-phosphate receptor antagonists EXELIXIS, INC. (US) 2014-07-29 US disclosed
US-20110288076-A1 Sphingosine-1-Phosphate Receptor Antagonists EXELIXIS, INC. (US) 2011-11-24 US disclosed
EP-2346821-A1 SPHINGOSINE-1-PHOSPHATE RECEPTOR ANTAGONISTS Exelixis, Inc. (US) 2011-07-27 EP disclosed
WO-2010045580-A1 SPHINGOSINE-1-PHOSPHATE RECEPTOR ANTAGONISTS EXELIXIS, INC. (US) 2010-04-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110288076-A1 Sphingosine-1-Phosphate Receptor Antagonists S1PR1, S1PR2, S1PR3 CYP1A2 4844/4885EPHX1 1982/4885HIF1A 3369/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.